Diagnostic, Clinical, and Therapeutic Aspects of Familial Hypercholesterolemia in Children

The clinical diagnosis of familial hypercholesterolemia (FH) in children is based on family history and laboratory findings. The best available value of low-density lipoprotein cholesterol (LDL-C) for the diagnosis of FH in children is >3.50 mmol/L (>135 mg/dL) when FH runs in the family. Levels below this concentration were only found in 4.3% of children that had a mutation in the LDL-receptor gene. In contrast, children with LDL-C equal to or above 3.50 mmol/L had 0.98 posttest probability of FH. Untreated FH carries a substantial burden of morbidity and mortality if left untreated or if inadequately treated. The guidelines of the American National Cholesterol Education Program suggested that drug treatment should be considered from the age of 10 years if LDL-C levels are greater than or equal to 4.9 mmol/L (190 mg/dL) or greater than or equal to 4.1 mmol/L (158 mg/dL) in the presence of other cardiovascular risk factors, including a positive family history of premature cardiovascular disease. Impaired flow mediated dilatation was more pronounced in FH children with a positive family history of premature cardiovascular disease. The currently prescribed diet is sometimes considered to be monotonous and can lead to problems with compliance. A reduction of the total intake fat and saturated fatty acids is important. Plant sterolesters should be evaluated in young FH children and can supplement drug and diet therapy, with an additional reduction of 10 to 15% of LDL-C. The use of resins leads to poor compliance, and statins are recommended for FH children and adolescents when drug treatment is indicated. Pravastatin, simvastatin, and atorvastatin decrease LDL-C 30 to 40% without serious adverse events and have a high degree of compliance.

Familial hypercholesterolemia - diet - drug treatment - children - adolescents

REFERENCES

• 1 Kwiterovich P O. Identification and treatment of heterozygous familial Hypercholesterolemia in children and adolescents.  Am J Cardiol. 1993;  72 30D-37D
• 2 Kwiterovich P O. Biochemical, clinical, epidemiological, genetic, and pathological data in the pediatric age group relevant to the cholesterol hypothesis.  Pediatrics. 1992;  89 525-584
• 3 Academy of Pediatrics . National Cholesterol Education Program: report of the expert panel on blood cholesterol levels in children and adolescents.  Pediatrics. 1992;  89 525-584
• 4 Wiegman A, Rodenburg J, De Jongh S et al.. Family history and cardiovascular risk in Familial Hypercholesterolemia: data in more than 1000 children.  Circulation. 2003;  107 1473-1478
• 5 Tonstad S. Stratification of risk in children with familial hypercholesterolemia with focus on psychological issues.  Nutr Metab Cardiovasc Dis. 2001;  11(Suppl 5) 64-67
• 6 Tonstad S, Refsum H, Sivertsen M, Christophersen B, Ose L, Ueland P M. Relation of homocysteine and lipid levels in children to premature cardiovascular death in male relatives.  Pediatr Res. 1996;  40 47-52
• 7 Tonstad S, Joakimsen O, Stensland-Bugge E et al.. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and controls.  Arterioscler Thromb Vasc Biol. 1996;  16 984-991
• 8 Tonstad S, Refsum H, Ose L, Ueland P M. The C677T mutation in the methylene-tetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine.  J Pediatr. 1998;  132 365-368
• 9 Umans-Eckenhausen M AW, Sijbrands E JG, Kastelein J JP, Defesche J C. Low-Density Lipoprotein-receptor gene mutations and cardiovascular risk in a large genetic cascade screening population.  Circulation. 2002;  106 3031-3036
• 10 Couture C, Brun L D, Szots F et al.. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia.  Arterioscler Thromb Vasc Biol. 1998;  18 1007-1012
• 11 Tell G S, Mittelmark M B, Vellar O D. Cholesterol, high density lipoprotein cholesterol and triglycerides during puberty: the Oslo Youth study.  Am J Epidemiol. 1985;  122 750-761
• 12 Setälä-Alto K, Viikarari J, Åkerblom H K, Kuusela V, Kontula K. DNA polymorphisms of the apolipoprotein B and A-I/C-III genes are associated with variations of serum low density lipoprotein cholesterol level in childhood.  J Lipid Res. 1991;  32 1477-1487
• 13 De Jongh S, Lilien M R, Bakker H D, Hutten B A, Kastelein J JP, Stroes E S. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia.  Atherosclerosis. 2002;  163 193-197
• 14 Tuzco E M, Kapadia S R, Tutar E et al.. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound.  Circulation. 2001;  103 2705-2710
• 15 Pathological Determinants of Atherosclerosis in Youth Research Group . Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from Pathological Determinants of Atherosclerosis in Youth (PDAY) Research Group.  JAMA. 1990;  264 3018-3024
• 16 Davis P H, Dawson J D, Riley W A, Lauer R M. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study.  Circulation. 2001;  104 2815-2819
• 17 Jarvisalo M S, Jartti L, Nanto-Salonen K et al.. Increased aortic intima-media thickens: a marker of preclinical atherosclerosis in high risk children.  Circulation. 2001;  104 2943-2947
• 18 Wiegman A, Rodenburg J, Gort J et al.. B-mode ultrasound material wall thickness measurements in children proven heterozygous for familial hypercholesterolemia.  Atherosclerosis. 2002;  3S 236
• 19 Poustie V J, Rutherford P. Dietary treatment for familial hypercholesterolemia.  Cochrane Database Syst Rev. 2001;  (2) , CD001918. Review
• 20 Mabuchi H, Yagi K, Haraki T, Matsushita H, Inazu A, Kajinami K, Koizumi J. Molecular genetics of cholesterol transport and cholesterol reverse transport disorders (familial hypercholesterolemia and CETP deficiency.  Ann N Y Acad Sci. 1995;  748 333-341
• 21 Grundy S M, Denke M A. Dietary influences on serum lipids and lipoproteins.  J Lipid Res. 1990;  31 1149-1172
• 22 Jacques H, Laurin D, Moorjani S et al.. Influence of diets containing cow's milk or soy protein beverages on plasma lipids in children with familial hypercholesterolemia.  J Am Coll Nutr. 1992;  11(Suppl) 69S-73S
• 23 Gylling H, Siimes M A, Miettinen T A. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia.  J Lipid Res. 1995;  36 1807-1812
• 24 Amundsen A L, Ose L, Nenseter M S, Ntanios F Y. Plant sterol ester-enriched spread lowers plasma total and LDL-cholesterol in children with familial hypercholesterolemia.  Am J Clin Nutr. 2002;  76 338-344
• 25 de Jongh S, Vissers M N, Rol P, Bakker H D, Kastelein J JP, Stroes E SG. Plant sterols lower LDL cholesterol without improving endothelial function in pre-pubertal children with familial hypercholesterolemia.  J Inherit Metab Dis. 2003;  26 343-351
• 26 National Cholesterol Education Program . Report of the Expert Panel on blood cholesterol levels in children and adolescents.  Pediatrics. 1992;  89 525-584
• 27 Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine in pubertal a prepubertal children with familial hypercholesterolemia.  J Pediatr. 1996;  129 42-39
• 28 Writing Group for the Dros Inf ServC Collaborative Research Group . Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. The Dietary Intervention Study in Children (Dros Inf ServC).  JAMA. 1995;  273 1429-1435
• 29 Tonstad S, Sivertsen M, Aksnes L, Ose L. Low dose colestipol in adolescents with familial hypercholesterolemia.  Arch Dis Child. 1996;  74 157-160
• 30 McCrindle B W, O'Neill M B, Cullen-Dean G, Helden E. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial.  J Pediatr. 1997;  130 266-273
• 31 Knapp H H, Schrott H, Ma P et al.. Efficacy and safety of combination simvastatin and colesevalam in patients with primary hypercholesterolemia.  Am J Med. 2001;  110 352-360
• 32 De Jongh S, Stalenhoef A FH, Tuohy M B, Mercuri M, Bakker H D, Kastelein J JP. Efficacy and tolerability of simvastatin in children with familial hypercholesterolemia.  Clinical Drug Investigation. 2002;  22 533-540
• 33 De Jongh S, Ose L, Szamosi T et al.. Efficacy and safety of statin therapy in children with familial Hypercholesterolemia.  Circulation. 2002;  106 2213-2237
• 34 McCrindle B, Ose L, Marais D. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia and/or severe hyperlipidemia: multicenter, randomized, placebo-controlled trial.  J Pediatr. 2003;  143 74-80
• 35 Stein E A, Illingworth D R, Kwiterovich P O et al.. Efficacy and safety of lovastin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.  JAMA. 1999;  281 137-144
• 36 Ducobu J, Brasseur D, Chaudron J M et al.. Simvastatin in children.  Lancet. 1992;  339 1488
• 37 Knipscheer H C, Boelen C C, Kastelein J JP et al.. Short term efficacy and safety of pravastatin in 72 children with familial Hypercholesterolemia.  Pediatr Res. 1996;  39 867-871
• 38 Lambert M, Lupien P J, Cagne C et al.. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin.  Pediatrics. 1996;  97 619-628
• 39 Stein E A, Illingworth D R, Kwiterovich P O et al.. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.  JAMA. 1999;  281 137-144
• 40 Newman T B, Browner W S, Hulley S B. The case against childhood cholesterol screening.  JAMA. 1990;  264 3039-3043
• 41 Holzman N A. The great god cholesterol.  Pediatrics. 1991;  87 943-945
• 42 Tonstad S, Nøvik T C, Vandvik I H. Psychosocial function during treatment for familial hypercholesterolemia.  Pediatrics. 1996;  98 249-255
• 43 de Jongh S, Kerckhoffs M C, Grootenhuis M A, Bakker H D, Heymans H S, Last B F. Quality of life, anxiety and concerns among statin-treated children with familial hypercholesterolaemia and their parents.  Acta Paediatr. 2003;  92 1096-1101